5 Best Information Technology Stocks To Buy For 2015

5 Best Information Technology Stocks To Buy For 2015: Isis Pharmaceuticals Inc.(ISIS)

Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using antisense drug discovery platform. The company?s antisense drug development programs focus on treating cardiovascular, metabolic, cancer, and severe neurodegenerative diseases. It has commercialized antisense drugs and has 24 drugs in development. Isis Pharmaceuticals, through Regulus Therapeutics Inc., also focuses on the discovery, development, and commercialization of microRNA-based therapeutics. The company has strategic alliances and collaboration agreements primarily with GlaxoSmithKline; Genzyme Corporation; Archemix Corp.; Alnylam Pharmaceuticals, Inc.; Bristol-Myers Squibb; Ortho-McNeil-Janssen Pharmaceuticals, Inc.; and Eli Lilly and Company. Isis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

Advisors' Opinion:

• [By Keith Speights]

  2. Isis Pharmaceuticals (NASDAQ: ISIS  )
  Isis shareholders are likely thrilled with 2013 thus far. The stock has soared over 170% year-to-date. These huge gains were driven primarily by FDA approval of Kynamro in January for treating rare diseasehomozygous familial hypercholesterolemia, or HoFH. More recently, Isis shares jumped onpositive mid-stage data for itsISIS-APOCIII Rx drug, which targets treatment ofpatients with high triglycerides and type 2 diabetes.

• [By Rebecca McClay]

  Isis Pharmaceuticals Inc. (Nasdaq: ISIS) this weekend announced interim data from an ongoing phase 2 study of ISIS-APOCIIIRx as a monotherapy in patients with very high to severely high triglycerides, or blood fat. Patients treated with ISIS-APOCIIIRx achieved statistically significant mean reductions of up to 79% in apolipoprotein C-III.

• [By MONEYMORNING.COM]

  Aegerion PharmaceuticalsInc. (Nasdaq: AEGR) developed a drug, Juxtapid, for a rare genetic condition calle! d homozygous familial hypercholesterolemia, or HoFH, that can raise a person's cholesterol levels to more than 1,000 mg/dL. A healthful level is considered to be less than 200 mg/dL. The disease largely affects kids, who can die of heart attack by age 2. Most are dead by age 11. When Juxtapid hit the market, it was the only therapy available. ISIS Pharmaceuticals Inc. (Nasdaq: ISIS) would soon join in the competition with its less expensive injectable drug, Kynamro, but Juxtapid had fewer side effects and could be administered orally.

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/5-best-information-technology-stocks-to-buy-for-2015-4.html